Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLS240 in Secondary Hyperparathyroidism on Hemodialysis
NCT05832931Phase 3Completed
- Sponsor
- Pathalys Pharma
- Start
- Apr 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of upacicalcet in secondary hyperparathyroidism (SHPT), sponsored by Pathalys Pharma. Started Apr 2023; status: completed.
02
Drugs
upacicalcet
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT05832931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05832931.